Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12D”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Testing effectiveness (Phase 2)WithdrawnNCT06690281
What this trial is testing

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Who this might be right for
Gastrointestinal CarcinomaPancreatic CancerHepatocellular Cancer+5 more
National Cancer Institute (NCI)
Early research (Phase 1)Looking for participantsNCT07094204
What this trial is testing

Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Who this might be right for
Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more
Astellas Pharma Inc 364
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06949761
What this trial is testing

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Who this might be right for
Solid Tumor
Qilu Pharmaceutical Co., Ltd. 240
Early research (Phase 1)Looking for participantsNCT06797336
What this trial is testing

PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

Who this might be right for
Solid Tumor
PAQ Therapeutics, Inc. 115
Testing effectiveness (Phase 2)Looking for participantsNCT07259590
What this trial is testing

GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Advanced Solid Tumors CancerPDACCRC (Colorectal Cancer)
Genfleet Therapeutics (Shanghai) Inc. 126
Early research (Phase 1)Looking for participantsNCT06619587
What this trial is testing

Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Genentech, Inc. 410
Testing effectiveness (Phase 2)WithdrawnNCT07026916
What this trial is testing

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07438106
What this trial is testing

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Who this might be right for
Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University 30
Early research (Phase 1)Active Not RecruitingNCT06818812
What this trial is testing

Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Incyte Corporation 30
Early research (Phase 1)Study completedNCT04853017
What this trial is testing

ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Who this might be right for
Minimal Residual DiseaseKRAS G12DKRAS G12R+9 more
Elicio Therapeutics 25
Early research (Phase 1)Looking for participantsNCT06403735
What this trial is testing

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

Who this might be right for
Non-small Cell Lung CancerColorectal CancerPancreatic Cancer+1 more
Qilu Pharmaceutical Co., Ltd. 250
Large-scale testing (Phase 3)Looking for participantsNCT07522073
What this trial is testing

Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Who this might be right for
Solid Tumors
Incyte Corporation 588
Large-scale testing (Phase 3)Looking for participantsNCT07409272
What this trial is testing

Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Who this might be right for
Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 614
Testing effectiveness (Phase 2)Looking for participantsNCT07023731
What this trial is testing

Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Who this might be right for
KRAS G12D MutationAdvanced Solid Cancer
Arvinas Inc. 159
Early research (Phase 1)Looking for participantsNCT06218914
What this trial is testing

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Who this might be right for
Non-small Cell Lung CancerColorectal CarcinomaPancreatic Ductal Adenocarcinoma+3 more
AstraZeneca 108
Early research (Phase 1)Looking for participantsNCT06962254
What this trial is testing

Imatinib and Trametinib for KRAS-mutated Solid Tumor

Who this might be right for
Solid Tumor Cancer
China Medical University Hospital 10
Early research (Phase 1)Looking for participantsNCT07207707
What this trial is testing

Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

Who this might be right for
Solid Tumor Malignancies
Kumquat Biosciences Inc. 78
Testing effectiveness (Phase 2)Study completedNCT03745326
What this trial is testing

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Who this might be right for
Gastrointestinal CancerPancreatic CancerGastric Cancer+2 more
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT05726864
What this trial is testing

ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaColorectal CancerKRAS G12D+11 more
Elicio Therapeutics 158
Testing effectiveness (Phase 2)Looking for participantsNCT06500676
What this trial is testing

GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Who this might be right for
KRAS G12D MutationsAdvanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc. 407
Load More Results